Your session is about to expire
← Back to Search
Nuclear Imaging for Cardiomyopathy (DISSOLvE Trial)
DISSOLvE Trial Summary
This trial will compare the effects of two different treatments on heart function in people with amyloidosis.
DISSOLvE Trial Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowDISSOLvE Trial Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.DISSOLvE Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I was eligible for or enrolled in the CARDIO-TTRansform study and had specific heart scans within the last year.N/A
- Group 1: Patients with transthyretin amyloid cardiomyopathy enrolled in CARDIO-TTRansform
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What are the odds of any negative side effects from this medication?
"This treatment has been shown to be safe in multiple trials, so it received a score of 3."
How many people can join this clinical test at most?
"Yes, according to information available on clinicaltrials.gov, this trial is still open for recruitment. The study was first posted on 1/19/2022 and was edited on 2/17/2022. A total of 80 patients are needed for the study, which is only being conducted at a single location."
Are there any available spots for new patients in this trial?
"Yes, that is accurate. The trial was posted on 1/19/2022 and was last updated on 2/17/2022. The study is looking for 80 patients from 1 location."
Does this research involve any elderly individuals?
"Eligibility for this clinical study requires that potential patients are between the ages of 60 to 90."
If I qualify, can I participate in this research?
"Eligible patients for this amyloidosis trial must be between 60 and 90 years old. Around 80 patients will be accepted in total."
Share this study with friends
Copy Link
Messenger